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Abstract  
BACKGROUND: Keratoacanthoma (KA) is a rapidly growing epithelial tumour with histopathologic and clinical 
features similar to squamous cell carcinoma (SCC) and a certain tendency toward spontaneous regression. 
CASE PRESENTATION: This article presents a unique and rare case of keratoacanthoma arising from the upper 
lip of a young male patient. These two features are in contrast to most of the reported cases in elder male 
individuals and on the lower lip. Relevant management protocol of the case has also been discussed. 
CONCLUSION: The article emphasises the significance of discerning such lesions from squamous cell carcinoma 
thus carrying diagnostic and therapeutic implications. However, in case of the dilemma it is prudent to assume 
that the lesion is SCC unless proved otherwise clinically and histologically. 
 
 
 
 
 
 
 
Introduction 
 
Keratoacanthoma (KA) is a rapidly growing 
epithelial tumour with histopathologic and clinical 
features similar to squamous cell carcinoma (SCC) 
and a certain tendency toward spontaneous 
regression.  
The etiologic factors involved in the 
development of keratoacanthoma are multiple. The 
role of UV radiation, chemical carcinogens, radiation 
therapy, genetic factors and various forms of 
antecedent trauma, including surgery, grafting, 
thermal burns, laser resurfacing, and vaccination have 
been documented [1] [2]. 
The lesion has a predilection for sun-exposed 
areas of face, neck, forearms. Lower lip location is six 
times more prevalent in comparison to upper lip [3]. 
The incidence increases with age, and it is 
more common after the age of 40 years with a slight 
predominance in males. The youngest reported is a 
15-year-old patient with traumatically induced 
keratoacanthoma [1]. It is also more common in light-
skinned persons. 
The short history relative to the size of the 
lesion and its typical clinical course carries diagnostic 
importance. It begins as a rapidly enlarging nodule 
over a period of 4 - 5 weeks, followed by a period of 
stability for another 4 - 8 weeks before undergoing 
spontaneous involution and complete resolution over 
a period of 6 months to 2 years with the expulsion of 
keratin leaving a depressed scar [4] [5].  
Keratoacanthomas show a tendency to a 
spontaneous resolution, and, in typical cases, some 
practitioners adopt the so-called watchful waiting 
approach, particularly in the cosmetically relevant 
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areas. However, KA can be easily misdiagnosed as 
SCC; therefore in most cases, surgical excision is 
considered the treatment of choice. 
 
 
Case Report 
 
A 31 – year - old Caucasian male was 
referred to our Maxillofacial surgery department for 
evaluation of a rapidly growing asymptomatic solitary 
nodule located on the mucocutaneous upper lip, 
present for the last 4 weeks.  
Clinical examination revealed a well-
demarcated, firm, dome-shaped nodule 1.5 cm in 
diameter with a small central keratinous plug (Figure 
1). The patient reported that the growth developed in 
the site of a previous scar result of a shaving accident 
two years ago. 
 
Figure 1: Patient presenting with KA of upper lip at the initial visit 
 
Working clinical diagnosis of solitary KA was 
made based on the history of short duration, rapid 
enlargement and morphology. Neck palpation did not 
reveal any suspicious lymph nodes. Past medical 
history was positive for vitiligo for which he was not 
interested in evaluation or therapy. The patient did not 
practice photoprotection. 
Subsequently, incision biopsy was performed 
under local anaesthesia. The histopathological 
evaluation confirmed the diagnosis of KA. We treated 
him with topical application of imiquimod cream 4 
times a week. The inflammatory reaction appeared in 
less than 2 weeks of application. The size of the 
tumour had decreased considerably, and central core 
expulsion was noted which left central depression 
surrounded by epithelial tags (Figure 2). 
 
Figure 2: The same patient after 2 weeks of treatment with topical 
Imiquimod 5% 
 
After 8 weeks, the mass was markedly 
flattened. At week 10 of therapy further improvement 
was recorded. The lesion had healed with a 
hypopigmented scar and remaining epithelial tags. 
The treatment was discontinued at this point. During 
the follow-up visit at week 12 further improvements 
were noted mainly in the smaller epithelial tags 
(Figure 3). During the subsequent follow up visits the 
improvement remained stable. We performed shave 
biopsy of the epithelial tags. Histopathology revealed 
no residual tumor elements. 
 
Figure 3: The same patient at week 12 (2 weeks after completion of 
treatment with topical Imiquimod 5% 
 
The lesion was photographed sequentially 
and documented until complete resolution.There was 
no recurrence after 12 months follow - up.The patient 
was also advised of the importance of photoprotection 
and referred for a dermatological evaluation. 
 Pancevski et al. Topical Imiquimod 5% as a Treatment Option in Solitary Facial Keratoacanthoma 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Mar 15; 6(3):531-535.                                                                                                                                                        533 
 
Discussion 
 
KA is an epithelial neoplasm which is clinically 
indistinguishable from SCC and has a strong 
histological similarity to well differentiated SCC 
[5][3][6]. 
Some authors are of the opinion that solitary 
KA represents an extremely low-grade SCC [7] [6].  
KA of the lip may arise from the skin rather 
than labial mucosa, which could well have been the 
case in the present patient [4] [6].  
Some authors consider KA as a self-limiting 
and benign tumour which undergoes spontaneous 
resolution in contrast to SCC which is considered a 
biologically malignant neoplasm with a potential to 
metastasise and local tissue destruction [4].  
Difficulties in differentiating between these 
two lesions are of huge importance since it carries 
therapeutic implications. Solitary large 
keratoacanthomas (KAs) of the head and neck 
present a management dilemma, due to the 
unpredictable clinical course. Therapeutic options 
proposed in the literature include complete excision, 
topical agents as podophyllin, 5 - fluorouracil and 
imiquimod [8], intralesional injection of bismuth, 
bleomycin, interferon Alfa - 2a, methotrexate [9] and 
triamcinolone (corticosteroids) [10], oral retinoids and 
photodynamic therapy, cryotherapy and radiotherapy 
with various outcomes [11]. 
Continued growth or significant pain despite 
the therapy, may suggest an underlying SCC in 
clinically classic KA. In these cases, surgery is 
recommended [12].  
Complete surgical excision is the treatment of 
choice, but complete excision can be too destructive 
and cosmetically or functionally unacceptable for 
tumours on cosmetically important sites. Despite this, 
the recommended treatment in literature for solitary 
KA of the lip is surgical excision because of the 
concern that the lesion may be a squamous cell 
carcinoma and clinical as well as histological 
differentiation of the two lesions is difficult [13]. 
The advantages of surgical excision include 
rapid treatment and availability of a complete 
specimen for histologic examination. 
Laser and cryotherapy as treatment 
modalities have some limitations as they can lead to 
substantial defects with functional or cosmetic 
morbidity, and do not allow for the histopathologic 
confirmation of the clinical diagnosis. Radiotherapy is 
an effective treatment of KA and offers the potential 
for a cure without requiring surgery or the need for 
reconstruction and has also been used as an 
adjunctive treatment following surgery, but it may not 
be advisable for younger patients, and it may pose an 
inconvenience due to the need for multiple hospital 
visits. 
 
 Systemic retinoids, such as isotretinoin, can 
be considered for patients with multiple lesions for 
which surgery is not adequate treatment modality. 
 Intralesional methotrexate (MTX),
 
5 -
fluorouracil, bleomycin, and steroids have all been 
used with success in patients who are either poor 
surgical candidates or have lesions not amenable to 
surgery because of size or location [10]. A 2007 
review of the use of intralesional injection of MTX on 
38 patients, showed a 92% clinical "resolution" rate. 
However, patients needed an average 2.1 injections 
to achieve it [9]. 
Intralesional methotrexate and 5 - FU have 
also been recommended for extensive lesions or 
lesions in more cosmetically sensitive areas, with 
advantages of intralesional methotrexate over 5 - FU 
including decreased number of injections decreased 
pain and lower cost.
 
Recently, there are a few reports of 
successful treatment of solitary KA by applying 5% 
imiquimod cream a member of the imidazoquinoline 
family of drugs, commercially available as Aldara, as a 
topical immunomodulator in the group of toll-like 
receptor 7 and 8 agonists. Imiquimod has a 
therapeutic role as an antiviral and antitumour drug.  
Most patients applied the cream 3 times a 
week for 5 to 7 months. Four to 11 weeks of 
application were required for the treatment, and 
sometimes adverse effects which depended on the 
inflammation resulting from the immunological 
reaction, such as burning sensation, itching, bleeding, 
stinging sensation, pain, erythema and erosions 
occurred. Other side effects include upper respiratory 
tract infection, sinusitis, and headache. Pregnant 
women should use imiquimod only if the potential 
benefits outweigh the risks. Clinicians should also be 
aware of pigmentation changes in patients [14]. 
The severity of side-effect is dose-dependent. 
In spite of these inconveniences, KA can be 
successfully treated with topical imiquimod, because 
of lower invasiveness and non-inferiority in the 
functional or cosmetic outcome. 
In previously reported cases of 
keratoacanthoma treated with imiquimod cream, the 
average duration to obvious improvement was 5.0 ± 
1.8 weeks, and that to complete remission was 7.4 ± 
2.2 weeks [8].  
In a report of two cases of KA-treated with 
imiquimod 5% cream in which the cream was applied 
daily for the first 6 or 7 days, and then reduced to 
alternate days according to the tolerance and 
erythema severity of the patient, the results show that 
frequent application of imiquimod at the initial 
treatment induces a prompt regression of KA and in 
both patients, the tumours fully regressed after five 
weeks of treatment [15]. 
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However, the analysis of previously reported 
cases showed no statistically significant difference in 
the duration to remission between cases applied once 
per day (median: 6.5 weeks; range of 5 to 8 weeks) 
and less than once per day (median: 6 weeks; range 
of 4 to 11 weeks). Similarly, the duration to complete 
remission was not related to age, size and the 
duration of KA. 
 In a previously reported analysis of 18 cases 
the medians of the duration to complete remission 
was 6 weeks in 14 previously reported cases (range 
of 4 to 11 weeks), and 10 weeks in another 4 cases 
(range of 9 to 11 weeks) [8]. 
Mature KA undergoes regression in 6 weeks, 
and topical imiquimod can promote the regression of 
KAs
 
[16]. 
In 18 - year retrospective study on the 
outcomes of keratoacanthomas with different 
treatment modalities the median duration to resolution 
was 6 months for intralesional, oral or topical 
medications [17].  
Also suggests that lesions treated with 
imiquimod cream should be considered for biopsy to 
judge histopathological remission after 5 to 8 weeks of 
application to shorten the duration of the treatment [8]. 
In cases of solitary KAs after rapid 
proliferation, a mature KA undergoes regression in 4 
to 6 weeks, leaving an atrophic and hypopigmented 
scar. This process from proliferation to regression 
usually takes about 4 to 9 months, but there are some 
persistent cases which take more than one year [8] 
[4]. 
Claims that spontaneously resolved 
keratoacanthomas leave poor quality scars that may 
need surgical revision were not confirmed in the 
illustrated series of 19 patients with solitary KAs which 
is the largest published to date [13]. 
There are contrasting opinions on cosmetic 
outcomes with spontaneous resolution of the KA 
versus therapeutic intervention. Treatment minimises 
scarring which helps better cosmetic results. 
Therefore, treatment is recommended in most cases. 
Some authors advocate surgical excision to result in a 
superior cosmetic outcome in comparison to lesions 
observed for spontaneous regression [4].  
Failure of treatment with any of these 
medications is indicated by a further progression of 
the lesion associated with pain. This may signal an 
underlying aggressive SCC in clinically classic large 
KAs.In these cases, complete surgical excision of the 
lesion with histologic evaluation is recommended.  
In conclusion, the results from our case report 
demonstrate that topical imiquimod can be an 
effective treatment option for solitary KAs when 
present in cosmetically sensitive areas. During 
treatment, the patient experienced only mild stinging 
sensation at the site of application. 
The choice of imiquimod as a therapeutic 
modality was based on patient’s age, lesion size and 
location, medication availability and the patient’s 
reluctance to receive intralesional injections. 
In our case, the outcome of the topical 
treatment with imiquimod was cosmetically and 
functionally superior to complete surgical excision. 
Treatment of keratoacanthoma (KA) is 
primarily surgical. Medical treatment should be 
reserved for exceptional cases where surgical 
intervention is either not feasible or desirable. For 
example, medical intervention may be appropriate in 
patients with multiple lesions, in lesions not amenable 
to surgery because of size or location, and in patients 
with comorbidities that dissuade surgical procedure. 
Most of the literature concerning medical 
intervention for keratoacanthoma is limited to case 
reports or case series. Be cautious when deciding to 
pursue medicine instead of surgical intervention and 
perform appropriate follow-up. 
Failure to treat keratoacanthoma 
appropriately may result in local destruction, 
unacceptably high levels of recurrence and 
metastasis, or in other cases, may result in an 
unfavourable risk-to-benefit ratio. 
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